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BACKGROUND: Hospitalization is an important outcome in pulmonary arterial hypertension
(PAH), shown previously to correlate with survival. Using the Registry to Evaluate Early and
Long-term PAH Disease Management (REVEAL Registry), we sought to characterize first-
time hospitalizations and their effect on subsequent hospitalization and survival in patients
with newly diagnosed disease .
METHODS: Patients with newly diagnosed PAH (n = 862, World Health Organization group 1)
were evaluated for first-time hospitalization. The hospitalizations were categorized as PAH
related or PAH unrelated based on the case report form. Categories for PAH-related and
PAH-unrelated hospitalizat ion were defined before independent review. Patient demographies
and disease characteristics are descr ibed as well as freedom from hospitalization and survival.
RESULTS: Of 862 patients, 490 (56.8%) had one or more hospitalizations postenrollment:
257 (52.4%) PAH related, 214 (43.7%) PAH unr elated, and 19 (3.9%) of undetermined causes.
The most common causes of PAH-related hospitalization were congestive heart failure and
placement/removal of a central venous catheter. Patients with PAH-related hospitalizations
were more likely to receive parenteral therapy, be in functional class III/IV, and have higher
risk scores before hospitalization at enrollment. Following discharge, 25.4% ± 3.2% and
31.0% ± 4.0% of patients with PAH-related and PAH-unrelated first hospitalization, respec-
tively, remained hospitalization -free for 3 years (P = .11). Survival estimates at 3 years post-
discharge were 56.8% ± 3.5% and 67.8% ± 3.6% (P = .037) for patients with PAH-related and
PAH-unr elated hospitalization, respectively.
CONCLUSIONS: In the REVEAL Registry, PAH-related hospitalization was associated with rel-
atively more rehospitalizations and worse survival at 3 years.
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 A composite end point encompassing hospitalization is 
considered a “level 1” end point, that is, a true measure 
of clinical effi  cacy. 1 Clinical studies of pulmonary arterial 
hypertension (PAH) have incorporated such composite 
clinical-worsening end points in their study design, 2-6 
including a recent long-term event-driven clinical study 
that used time to PAH-related death or PAH-related 
hospitalization as a critical secondary end point. 7 Clin-
ical worsening, defi ned as worsening functional class, 
  15% reduction in 6-min walk distance, need for par-
enteral prostacyclin analog therapy, or all-cause hospi-
talization, has been found to predict mortality at 1 year 
aft er any parameter of clinical worsening is met. 8,9 Fur-
thermore, hospitalization among patients with PAH 
appears to be associated with increased subsequent 
mortality. 10-12 Hospitalization—and rehospitalization—
therefore, represent a substantial burden both for patients 
with PAH and for the health-care system. 13 
 Reports that characterize hospitalizations and/or calcu-
late subsequent survival posthospitalization in patients 
with PAH have identifi ed factors at hospital admission 
that correlate with subsequent survival. 10-12,14 However, 
it is diffi  cult to generalize these reports to routine prac-
tice because of their single-center experience and their 
focus on only certain causes of PAH (World Health 
Organization [WHO] group 1 pulmonary hypertension). 
Also, these reports describe patients with disease-related 
hospitalizations and not patients with disease-unrelated 
hospitalizations or no hospitalizations, characterizations 
that could elucidate the relative burdens of the disease, 
hospitalization for any reason, and hospitalization spe-
cifi cally related to disease. 
 Th e Registry to Evaluate Early and Long-term PAH 
Disease Management (REVEAL Registry) is an observa-
tional registry that provides current information about 
the demographics, disease course, and management of 
patients with PAH. 15 In this retrospective analysis, we 
characterize fi rst-time hospitalizations aft er enrollment 
among patients with newly diagnosed disease in the 
REVEAL Registry and describe demographics and clin-
ical characteristics of patients at enrollment and/or 
diagnosis, by category of hospitalization. We also exam-
ine the eff ect of fi rst-time hospitalization on risk of 
subsequent hospitalization and on survival. 
 Materials and Methods 
 Th e design of the REVEAL Registry has been described previously. 15 
Briefl y, the REVEAL Registry is a multicenter observational, prospec-
tive registry involving 55 university-affi  liated and community hospital-
based pulmonary hypertension centers in the United States. Each of the 
participating sites received institutional review board approval ( e-Table 1 ). 
Patients with PAH (WHO group 1 pulmonary hypertension; Venice 
2003 defi nition), 16 confi rmed by right-sided heart catheterization, were 
enrolled consecutively from March 2006 through December 2009 aft er 
providing informed consent. 
 For this analysis we evaluated only patients with newly diagnosed dis-
ease with qualifying right-sided heart catheterization within 90 days of 
enrollment with hemodynamics measured at rest. Only patients with 
pulmonary capillary wedge pressure   15 mm Hg were included. 
 First-time postenrollment hospitalizations were independently reviewed 
by three investigators (C. D. B., P. K. L., and R. E. S.) and categorized 
as PAH related or not primarily related to PAH (hereaft er referred to 
as “PAH unrelated”) based on information in case report forms (dates 
of hospital admission and discharge, primary discharge diagnosis, rea-
son for hospitalization, disease characteristics, and treatments prior 
to admission). Secondary diagnoses were not available, so the deter-
mination of PAH related vs PAH unrelated was made based only on 
the primary diagnosis. Categories for PAH-related hospitalization 
were determined before review, and any one of these categories would 
have constituted a PAH-related hospitalization. Categories for the 
PAH-unrelated hospitalizations were also determined before review, 
but some modifi cations were made aft erward to cover all categories 
with more than one admission—any single discharge diagnosis that 
did not fi t in a category was classifi ed as “other.” More than one cate-
gory could have been present at any given admission, and in those 
situations the primary discharge diagnosis was the determinate of 
hospitalization causality. Data download for these analyses occurred on 
February 4, 2013. 
 Group diff erences in patient demographics and disease characteristics 
determined at enrollment were tested with Pearson  x 2 , Mantel-Haenszel  x 2 , 
or  t tests for binary, ordinal, and continuous variables, respectively. 
For variables with highly skewed distributions, the Wilcoxon test was 
used. Kaplan-Meier estimates for freedom from hospitalization and 
for survival were computed for distinct at-risk periods: (1) for the full 
cohort (ie, hospitalized and nonhospitalized patients), the risk period 
began at enrollment; (2) for patients with a fi rst-time hospitalization, 
the risk period (for freedom from event following hospitalization) began 
at hospital discharge; (3) for patients event-free through the fi rst year 
of follow-up, the at-risk period for future follow-up began at 365 days 
aft er enrollment. 
 Results 
 Causes of PAH-Related and 
PAH-Unrelated Hospitalizations 
 Of 862 patients in the analysis cohort, 490 (56.8%) had 
at least one hospitalization during follow-up on study, 
and 372 (43.2%) had none ( Fig 1 ). Of the 490 fi rst-time 
hospitalizations, 257 (52.4%) were for causes clearly 
related to PAH, 214 (43.7%) were for PAH-unrelated 
causes that were considered related to comorbidity, and 
19 (3.9%) could not be characterized as PAH related or 
unrelated because of insufficient data ( Fig 1 ). The 
median time from right-sided heart catheterization 
diagnosis to study enrollment was 26 days. 
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 Figure 1 – Diagram of patients included in the analysis cohort. Patient groups shown in gray boxes were not included in the analysis cohort. 
PAH  5 pulmonary arterial hypertension; PCWP  5 pulmonary capillary wedge pressure; REVEAL  5 Registry to Evaluate Early and Long-term PAH 
Disease Management . 
 Among the 257 patients hospitalized for PAH-related 
causes, congestive heart failure (n  5 81, 31.5%) and 
placement or removal of a central venous catheter 
(n  5 63, 24.5%) were the two most common causes cited 
at admission ( Table 1 ). Other common causes for fi rst-
time hospitalization were the initial IV line insertion 
(n  5 30, 11.7%), which represents the initiation of IV 
therapy, and the escalation of therapy for PAH (n  5 23, 
8.9%). A total of 21 PAH-related hospitalizations (8.2%) 
were associated with catheter infection: 11 occurring in 
the fi rst year, three in the second year, and seven in the 
third year or later. 
 Among the 214 patients hospitalized for PAH-unrelated 
causes, non-line-related infections were cited most com-
monly: PAH-unrelated infections (n  5 38, 21.1%) and 
pneu monia (n  5 34, 15.9%) ( Table 1 ). Other common 
diagnoses at the time of fi rst hospitalization were surgery/
procedures (n  5 24, 11.2%) and hemorrhage (n  5 19, 8.9%). 
 Patient Demographics and Disease Characteristics 
at Enrollment That Predict Hospitalization 
 Patients hospitalized for any reason were more likely 
than patients not hospitalized to have comorbidities 
(diabetes and depression) and to have more severe PAH 
at enrollment, as measured by functional class, presence 
of pericardial eff usion, higher mean atrial pressure, 
lower cardiac index, and higher REVEAL Registry risk 
score. Patients with hospitalizations also had signifi -
cantly longer follow-up from enrollment than patients 
without hospitalizations ( Table 2 ). 
 Comparison between PAH-related and PAH-unrelated 
groups revealed few diff erences at enrollment. In partic-
ular, patients with PAH-related hospitalizations were 
less likely than patients with PAH-unrelated hospitaliza-
tions to be  , 18 years of age and more likely to have 
more severe PAH, as measured by functional class and 
lower cardiac index. Length of follow-up from enrollment 
was also shorter for the PAH-related group ( Table 2 ). 
 Characterization of PAH-Related and 
PAH-Unrelated Hospitalizations 
 Hospitalization-related characteristics were similar 
overall between the PAH-related and PAH-unrelated 
groups, with the notable exception that patients with 
PAH-related hospitalizations were more likely to be on 
parenteral therapy, to be in functional class III or IV prior 
to hospitalization, and to have a higher REVEAL Registry 
risk score prior to hospitalization ( Table 3 ). Further 
description of the type and timing of PAH-related 
hospitalizations, including distribution of specifi c causes 
for hospitalization over time, is provided in the online 
supplement ( e-Figs 1, 2 ,  e-Table 2 ). 
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 TABLE 1  ]  Reasons for First-Time Hospitalization 
Related and Unrelated to PAH 
Reason No. (%)
Patients with ¿ rst-time PAH-related 
   hospitalization (n  5 257)
 Congestive heart failure 81 (31.5)
 Placement or removal of central 
  venous catheter
63 (24.5)
 Initial IV line insertion 30 (11.7)
 Escalation in PAH treatment 23 (8.9)
 Catheter infection 21 (8.2)
 Syncope 12 (4.7)
 Conversion of IV line 7 (2.7)
 PH medication-related adverse event 5 (1.9)
 Transplant 5 (1.9)
 Right-sided heart catheterization 4 (1.6)
 Atrial septostomy 0 (0.0)
 PAH-related but uncharacterized 42 (16.3)
Patients with ¿ rst-time PAH-unrelated 
   hospitalization (n  5 214)
 PAH-unrelated infections (not pneumonia) 38 (21.1)
 Pneumonia 34 (15.9)
 Surgery/procedure 24 (11.2)
 Hemorrhage 19 (8.9)
 GI disorder (not hemorrhage or infection) 12 (5.6)
 Arrhythmia 11 (5.1)
 Respiratory failure 11 (5.1)
 Anemia 10 (4.7)
 Noncardiac chest pain 7 (3.3)
 Respiratory disorder (not pneumonia 
   or respiratory failure)
7 (3.3)
 Sepsis 7 (3.3)
 Trauma/fracture 7 (3.3)
 Electrolyte abnormality 6 (2.8)
 Renal failure 5 (2.3)
 Hemoptysis 4 (1.9)
 Neurologic disorder (not stroke) 4 (1.9)
 Acute coronary syndrome a 4 (1.9)
 Hepatic failure 2 (0.9)
 Ischemic stroke 2 (0.9)
 Pain (not chest pain) 2 (0.9)
 Psychiatric disorder 2 (0.9)
 Thromboembolism 4 (1.9)
 Other 15 (7.0)
 Reasons are not mutually exclusive; a patient could have been 
hospitalized for more than one reason. PAH  5 pulmonary arterial 
hypertension; PH  5 pulmonary hypertension. 
 a Includes angina and myocardial infarction. 
 Freedom From Hospitalization 
 For the entire analysis cohort at 3 years from enroll-
ment, 45.4%   1.8% of patients remained free from 
hospitalization ( Fig 2A ). Among patients who were hos-
pitalized and discharged alive following the fi rst hospi-
talization, 25.4%   3.2% of patients with PAH-related 
and 31.0%   4.0% of patients with PAH-unrelated fi rst 
hospitalization remained free from a second hospitaliza-
tion at 3 years postdischarge ( P  5 .11) ( Fig 2B ). For 
patients who remained hospitalization-free for 1 year 
postenrollment, 53.7%   2.5% remained free from admis-
sion aft er an additional 3 years of follow-up ( Fig 2C ). 
 Survival 
 In-hospital mortality was signifi cantly higher for PAH-
related hospitalizations compared with PAH-unrelated 
hospitalizations (5.4% vs 1.4%,  P  5 .024) ( Table 3 ). 
Among those discharged alive following fi rst-time hos-
pitalization, the survival estimate at 3 years postdischarge 
was lower for patients with PAH-related hospitalization 
than for patients with PAH-unrelated hospitalization 
(56.8%   3.5% vs 67.8%   3.6%,  P  5 .037) ( Fig 3A ). 
Among patients who remained hospitalization-free for 
1 year postenrollment, survival aft er 3 additional years 
of follow-up was 77.8%   1.9% ( Fig 3B ). 
 Discussion 
 Th e REVEAL Registry represents the largest database so 
far of patients newly diagnosed with PAH (WHO group 1) 
analyzed for characteristics of fi rst-time hospitaliza-
tion. Th e burden of disease in patients with PAH is 
substantial, as evidenced by the high incidence of hospi-
talization (57%) in this cohort of patients with newly 
diagnosed disease from the prospective REVEAL Registry. 
Our findings clearly demonstrate that all-cause hos-
pitalization is very common among patients with 
newly diagnosed disease. In particular, the rate of PAH-
unrelated hospitalizations in this REVEAL Registry 
cohort is relatively high, suggesting that the term “PAH-
unrelated” is a misnomer and that this category of hos-
pitalization actually refl ects a degree of risk conferred 
by the PAH comorbidity. For example, a primary dis-
charge diagnosis of “pneumonia” on the case report 
form would result in a categorization of that patient’s 
hospitalization as PAH-unrelated. However, if PAH 
predisposes the patient to non-line-related infections 
such as pneumonia or if an infection such as pneumonia 
were to precipitate congestive heart failure, then one 
could argue that the hospitalization is truly PAH related. 
Th e current study is unable to address that methodo-
logic challenge. Although 53% of patients had fi rst-time 
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 TABLE 3  ]  Characterization of Hospitalizations, by Type of Hospitalization 
Parameter PAH Related (A) PAH Unrelated (B) All a (C)  P Value (A vs B)
No. of patients b 257 214 471 …
Length of stay, d
 No. of patients 248 202 450 .13 c 
 Mean (SD) 6.5 (7.9) 10.3 (38.7) 8.2 (26.6) …
 Median 4.0 4.0 4.0 …
 Length of stay   7 d, No. (%) 73 (29.4) 54 (26.7) 127 (28.2) .53 d 
Total hospital days in the year 
   after ¿ rst admission
 No. of patients 248 202 450 .47 c 
 Mean (SD) 14.3 (24.7) 16.6 (42.6) 15.3 (33.9) …
 Median 7.5 6.5 7.0 …
 Total days   14 d, No. (%) 74 (28.8) 48 (22.4) 122 (25.9) .12 d 
No. of readmissions during study
 No. of patients 257 214 471 .42 c 
 Mean (SD) 1.8 (2.6) 2.1 (3.7) 1.9 (3.1) …
 None, No. (%) 93 (36.2) 90 (42.1) 183 (38.9) …
 1 readmission, No. (%) 71 (27.6) 47 (22.0) 118 (25.1) …
   2 readmissions, No. (%) 93 (36.2) 77 (36.0) 170 (36.1) …
Average length of follow-up from 
   hospital discharge, y
 No. of patients 241 211 452 .91 c 
 Mean (SD) 2.2 (1.7) 2.2 (1.5) 2.2 (1.6) …
Hospitalization rate, No. per year 
   of follow-up
 No. of patients 241 211 452 .10 c 
 Mean (SD) 2.2 (5.6) 1.5 (3.0) 1.8 (4.6) …
No. of PAH medications at 
   admission, No. (%)
 None 26 (10.1) 26 (12.1) 52 (11.0) .82 d 
 Monotherapy 133 (51.8) 106 (49.5) 239 (50.7) …
 Double therapy 79 (30.7) 69 (32.2) 148 (31.4) …
 Triple therapy 19 (7.4) 13 (6.1) 32 (6.8) …
 Parenteral therapy 111 (45.5) 43 (21.6) 154 (34.8)  , .001 d 
 Warfarin use 76 (29.9) 48 (22.5) 124 (26.6) .072 d 
 Diuretic use 120 (47.2) 85 (39.9) 205 (43.9) .11 d 
Most recent FC assessment prior 
   to hospitalization, No. (%)
 FC I 12 (4.9) 7 (3.5) 19 (4.3) .003 e 
 FC II 58 (23.8) 71 (35.9) 129 (29.2) …
 FC III 136 (55.7) 107 (54.0) 243 (55.0) …
 FC IV 38 (15.6) 13 (6.6) 51 (11.5) …
(Continued)
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TABLE 3 ] (continued)
Parameter PAH Related (A) PAH Unrelated (B) All a (C)  P Value (A vs B)
REVEAL Registry risk score prior 
   to hospitalization
 No. of patients 257 214 471 .018 c 
 Mean (SD) 8.5 (2.3) 8.0 (2.5) 8.3 (2.4) …
 In-hospital death, No. (%) 14 (5.4) 3 (1.4) 17 (3.6) .024 f 
 a All patients with   1 hospitalization (C) includes patients with PAH-related (A) and PAH-unrelated (B) hospitalizations. Nineteen patients with 
undetermined causes of hospitalization were not included in this cohort. FC  5 New York Heart Association functional class. See  Table 1 legend for 
expansion of other abbreviation. 
 b The total number of patients in each cohort with data at enrollment for each parameter is assumed to be 257 (A), 214 (B), and 471 (C), unless 
otherwise noted. 
 c P value is computed using  t test. 
 d P value is computed using  x 2 test. 
 e P value is computed using Mantel-Haenszel test. 
 f P value is computed using Fisher exact test. 
hospitalizations that were clearly related to PAH, it is 
unclear what proportion of so-called “PAH-unrelated” 
hospitalizations were truly incidental or precipitated by 
the PAH comorbidity to some extent. 
 Patients in this analysis who were hospitalized for any 
reason had a higher prevalence of comorbidities and 
more severe PAH at enrollment, as measured by func-
tional class, pericardial eff usion, mean right atrial pres-
sure, and REVEAL Registry risk score, compared with 
patients without hospitalizations. Fewer diff erences at 
enrollment distinguished between patients with PAH-
related and PAH-unrelated hospitalizations, although 
patients with PAH-related hospitalizations presented 
with more severe PAH at the time of fi rst admission. 
Th e lack of diff erences between the PAH-related and 
PAH-unrelated groups at enrollment is an important 
point, given our fi nding that both in-hospital and post-
discharge survival are signifi cantly worse for patients 
hospitalized for PAH-related reasons, despite the similar 
frequencies at which PAH-related and PAH-unrelated 
hospitalizations occur. Th e worse outcomes were seen in 
the PAH-related group despite  . 46% use of parenteral 
prostanoids at the time of the fi rst hospitalization com-
pared with 22% in the PAH-unrelated group. 
 Hospital readmission is common for patients with PAH, 
especially those whose fi rst hospitalization was PAH 
related. Only 25.4% of patients discharged aft er a PAH-
related hospitalization remained free from readmission 
3 years later. Furthermore, hospitalization for any cause 
increases overall risk of death, an association that has 
been documented previously. 8 Even for patients with no 
hospitalizations in the fi rst year aft er enrollment, almost 
one-half experience at least one hospitalization over the 
subsequent 3 years, despite treatment of PAH, indicating 
that surviving the fi rst year hospitalization-free does not 
strongly relate to the likelihood of future hospitalization. 
 Mean total hospital days in the year aft er fi rst admission 
(inclusive of fi rst admission) for all patients with at least 
one hospitalization was 15.3 days (median, 7.0 days), 
which represents a signifi cant burden for both the health-
care system as a whole and for individual patients. For 
our analysis, we did not evaluate the burden of cost for 
PAH-related hospitalization. One retrospective study 
estimated total per-patient per-month costs (including 
inpatient and outpatient costs) at $4,021 for patients 
with PAH. 17 Extrapolating from that fi gure, we calculate 
that total costs for PAH were about $188 million in 2012 
(assuming a prevalence of 12.4 cases per million 18 and 
313.9 million people in the United States in 2012 19 ). 
Based on the attention currently paid to left -sided heart 
failure by regulatory and reimbursement third parties, 20 
for which total costs are estimated at $30 billion in the 
United States in 2013, 21 one might expect similar 
emphasis to be directed at PAH-related hospitalizations, 
particularly those for heart failure. 
 Th is analysis may have been limited by several factors. 
First, the analysis presented here was retrospectively 
determined and may be limited by the biases inherent to 
any analysis that is not fully prespecifi ed prospectively 
before the data are collected. Th is includes the selection 
of the cohort for the analysis. We chose to focus on patients 
with newly diagnosed disease to minimize survivor bias, 
but it must be noted that there was, typically, a delay of 
about 1 month between diagnosis and enrollment. Perhaps 
more importantly, at the time of the fi rst hospitalization, 
patients no longer had newly diagnosed disease, but rather 
those results should be generalized to patients being 
discharged aft er their fi rst postdiagnosis hospitalization. 
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 Second, the categorization of hospitalization as PAH 
related or unrelated was made based on specifi c retro-
spective data available from the case report form, and in 
42 cases (16.3%) of hospitalization causality related to 
PAH could not be determined. Access to full patient charts 
was not available at the time of investigator review of the 
data. Th ird, the hospitalization subcategories overlapped. 
For example, “placement or removal of a central venous 
 
 Figure 2 – A-C, Kaplan-Meier estimates of freedom from hospitalization 
for (A) all patients from time of enrollment; (B) patients with a fi rst-time 
hospitalization from time of discharge, by type of hospitalization; and 
(C) patients with no hospitalization in the fi rst year of follow-up 
(including patients with no hospitalizations and patients with fi rst-time 
hospitalizations occurring aft er the fi rst year of follow-up) from 1 y aft er 
enrollment. See  Figure 1 legend for expansion of abbreviation. 
  
 Figure 3 – A, B, Kaplan-Meier estimates of survival for (A) patients 
with a fi rst-time hospitalization from time of discharge, by type of hospi-
talization; and (B) patients with no hospitalization in the fi rst year of 
follow-up (including patients with no hospitalizations and patients with 
fi rst-time hospitalizations occurring aft er the fi rst year of follow-up) from 
1 y aft er enrollment. See  Figure 1 legend for expansion of abbreviation. 
catheter” may overlap with “initial IV line insertion.” 
Some of the overlap was mitigated by ensuring that the 
category “PAH-unrelated infection” excluded  both 
 “catheter infection” (PAH-related) and “pneumonia” 
(PAH-unrelated hospitalization), so that these three 
categories of infection were considered separately. Fourth, 
the signifi cantly longer period of follow-up for patients 
with hospitalizations, compared with patients without 
hospitalizations, may be a source of bias, since the likeli-
hood of a hospitalization event increases with time. 
 Conclusions 
 PAH is associated with a considerable burden of disease 
(as measured by all-cause hospitalization). Patients who 
are more severely ill (ie, with more severe PAH or mul-
tiple comorbidities) are at higher risk for all-cause hos-
pitalization. Th e degree of freedom from hospitalization 
is very poor aft er the fi rst hospitalization, regardless of 
the cause. Prognosis is relatively better for patients with 
no hospitalizations in the fi rst year or fi rst hospitalization 
occurring aft er 1 year, but it nevertheless remains poor. 
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